Homebiotech stocks

biotech stocks

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

December 19, 2022

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

December 19, 2022

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 17, 2022

EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

December 16, 2022

EIGER ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eiger Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm

EIGER ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eiger Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm

December 16, 2022

ROSEN, A TOP RANKED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

ROSEN, A TOP RANKED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 16, 2022

Ultragenyx’s (RARE) Portfolio of Marketed Drugs Aids Growth

Ultragenyx’s (RARE) Portfolio of Marketed Drugs Aids Growth

December 16, 2022

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

December 16, 2022

Here’s Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

Here’s Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

December 16, 2022

Oncocyte Announces Initiatives to Focus Corporate Strategy

Oncocyte Announces Initiatives to Focus Corporate Strategy

December 16, 2022

« 1 … 9 10 11 12 13 … 558 »